# Lipocine Inc.: financial statements, quarterly

LPCN · Nasdaq · CIK 1535955 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lpcn.md) · [Financials](/companies/lpcn/financials.md) · [Filings](/companies/lpcn/filings.md) · [Insiders](/companies/lpcn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lpcn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [(3,122)](/filings/0001493152-24-043893.md) | [216 d](/filings/0001493152-25-010146.md) | [7,617](/filings/0001641172-25-009180.md) | [89.6](/filings/0001493152-25-011588.md) | [0.0 d](/filings/0001493152-25-021007.md) | [3,491 d](/filings/0001493152-26-009411.md) | [93.9](/filings/0001493152-26-021637.md) | [623](/filings/0001493152-26-035909.md) | [115](/filings/0001493152-25-021007.md) | [1,145 d](/filings/0001493152-26-009411.md) | [119](/filings/0001493152-26-021637.md) | [190](/filings/0001493152-26-035909.md) |
| Research and development | $k | [2,879](/filings/0001493152-24-043893.md) | [1,675 d](/filings/0001493152-25-010146.md) | [2,819](/filings/0001641172-25-009180.md) | [1,875](/filings/0001493152-25-011588.md) | [1,585](/filings/0001493152-25-021007.md) | [1,073 d](/filings/0001493152-26-009411.md) | [1,062](/filings/0001493152-26-021637.md) | [2,137](/filings/0001493152-26-035909.md) | [2,708](/filings/0001493152-25-021007.md) | [2,678 d](/filings/0001493152-26-009411.md) | [2,764](/filings/0001493152-26-021637.md) | [2,041](/filings/0001493152-26-035909.md) |
| Operating income | $k | [(7,043)](/filings/0001493152-24-043893.md) | [(2,593) d](/filings/0001493152-25-010146.md) | [3,223](/filings/0001641172-25-009180.md) | [(3,293)](/filings/0001493152-25-011588.md) | [(2,630)](/filings/0001493152-25-021007.md) | [1,545 d](/filings/0001493152-26-009411.md) | [(2,090)](/filings/0001493152-26-021637.md) | [(2,404)](/filings/0001493152-26-035909.md) | [(3,361)](/filings/0001493152-25-021007.md) | [(2,516) d](/filings/0001493152-26-009411.md) | [(3,849)](/filings/0001493152-26-021637.md) | [(2,842)](/filings/0001493152-26-035909.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0 d](/filings/0001493152-24-043893.md) | [0.6 d](/filings/0001493152-25-010146.md) | [0.2](/filings/0001641172-25-009180.md) | [0.5](/filings/0001493152-25-011588.md) | [0.0 d](/filings/0001493152-25-021007.md) | [0.0 d](/filings/0001493152-26-009411.md) | [0.2](/filings/0001493152-26-021637.md) | [0.0 d](/filings/0001493152-26-035909.md) | [0.0 d](/filings/0001493152-25-021007.md) | [0.0 d](/filings/0001493152-26-009411.md) | not reported | [0.2](/filings/0001493152-26-035909.md) |
| Net income | $k | [(6,651)](/filings/0001493152-24-043893.md) | [(2,282) d](/filings/0001493152-25-010146.md) | [3,514](/filings/0001641172-25-009180.md) | [(3,069)](/filings/0001493152-25-011588.md) | [(2,219)](/filings/0001493152-25-021007.md) | [1,782 d](/filings/0001493152-26-009411.md) | [(1,865)](/filings/0001493152-26-021637.md) | [(2,206)](/filings/0001493152-26-035909.md) | [(3,187)](/filings/0001493152-25-021007.md) | [(2,370) d](/filings/0001493152-26-009411.md) | [(3,672)](/filings/0001493152-26-021637.md) | [(2,623)](/filings/0001493152-26-035909.md) |
| Diluted EPS | $ per share | [(1.27)](/filings/0001493152-24-043893.md) | not reported | [0.66](/filings/0001641172-25-009180.md) | [(0.56)](/filings/0001493152-25-011588.md) | [(0.44)](/filings/0001493152-25-021007.md) | not reported | [(0.35)](/filings/0001493152-26-021637.md) | [(0.41)](/filings/0001493152-26-035909.md) | [(0.59)](/filings/0001493152-25-021007.md) | not reported | [(0.54)](/filings/0001493152-26-021637.md) | [(0.32)](/filings/0001493152-26-035909.md) |
| Basic EPS | $ per share | [(1.26)](/filings/0001493152-24-043893.md) | not reported | [0.66](/filings/0001641172-25-009180.md) | [(0.57)](/filings/0001493152-25-011588.md) | [(0.41)](/filings/0001493152-25-021007.md) | not reported | [(0.35)](/filings/0001493152-26-021637.md) | [(0.41)](/filings/0001493152-26-035909.md) | [(0.59)](/filings/0001493152-25-021007.md) | not reported | [(0.54)](/filings/0001493152-26-021637.md) | [(0.32)](/filings/0001493152-26-035909.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.1](/filings/0001493152-23-039861.md) | [4.8](/filings/0001493152-25-010146.md) | [3.1](/filings/0001493152-24-018311.md) | [5.6](/filings/0001493152-24-030648.md) | [3.7](/filings/0001493152-24-043893.md) | [6.2](/filings/0001493152-26-009411.md) | [3.4](/filings/0001641172-25-009180.md) | [6.0](/filings/0001493152-25-011588.md) | [3.9](/filings/0001493152-25-021007.md) | [5.2](/filings/0001493152-26-035909.md) | [5.0](/filings/0001493152-26-021637.md) | [5.0](/filings/0001493152-26-035909.md) |
| Current assets | $m | [24.6](/filings/0001493152-23-039861.md) | [22.9](/filings/0001493152-25-010146.md) | [25.3](/filings/0001493152-24-018311.md) | [22.9](/filings/0001493152-24-030648.md) | [20.5](/filings/0001493152-24-043893.md) | [22.3](/filings/0001493152-26-009411.md) | [20.3](/filings/0001641172-25-009180.md) | [18.4](/filings/0001493152-25-011588.md) | [15.9](/filings/0001493152-25-021007.md) | [16.9](/filings/0001493152-26-035909.md) | [25.2](/filings/0001493152-26-021637.md) | [23.7](/filings/0001493152-26-035909.md) |
| Total assets | $m | [24.8](/filings/0001493152-23-039861.md) | [23.0](/filings/0001493152-25-010146.md) | [25.4](/filings/0001493152-24-018311.md) | [23.0](/filings/0001493152-24-030648.md) | [20.7](/filings/0001493152-24-043893.md) | [22.5](/filings/0001493152-26-009411.md) | [20.5](/filings/0001641172-25-009180.md) | [18.6](/filings/0001493152-25-011588.md) | [16.1](/filings/0001493152-25-021007.md) | [17.0](/filings/0001493152-26-035909.md) | [25.4](/filings/0001493152-26-021637.md) | [23.8](/filings/0001493152-26-035909.md) |
| Current liabilities | $m | [2.2](/filings/0001493152-23-039861.md) | [2.6](/filings/0001493152-25-010146.md) | [1.5](/filings/0001493152-24-018311.md) | [1.8](/filings/0001493152-24-030648.md) | [1.6](/filings/0001493152-24-043893.md) | [1.5](/filings/0001493152-26-009411.md) | [1.3](/filings/0001641172-25-009180.md) | [1.4](/filings/0001493152-25-011588.md) | [1.9](/filings/0001493152-25-021007.md) | [2.5](/filings/0001493152-26-035909.md) | [2.5](/filings/0001493152-26-021637.md) | [2.1](/filings/0001493152-26-035909.md) |
| Total liabilities | $m | [2.3](/filings/0001493152-23-039861.md) | [2.6](/filings/0001493152-25-010146.md) | [1.5](/filings/0001493152-24-018311.md) | [1.8](/filings/0001493152-24-030648.md) | [1.6](/filings/0001493152-24-043893.md) | [1.5](/filings/0001493152-26-009411.md) | [1.3](/filings/0001641172-25-009180.md) | [1.4](/filings/0001493152-25-011588.md) | [1.9](/filings/0001493152-25-021007.md) | [2.5](/filings/0001493152-26-035909.md) | [2.5](/filings/0001493152-26-021637.md) | [2.1](/filings/0001493152-26-035909.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [22.5](/filings/0001493152-24-043893.md) | [20.4](/filings/0001493152-26-009411.md) | [24.0](/filings/0001493152-25-011588.md) | [21.2](/filings/0001493152-25-021007.md) | [19.1](/filings/0001493152-25-021007.md) | [21.0](/filings/0001493152-26-035909.md) | [19.2](/filings/0001493152-26-035909.md) | [17.1](/filings/0001493152-26-035909.md) | [14.1](/filings/0001493152-25-021007.md) | [14.5](/filings/0001493152-26-035909.md) | [22.8](/filings/0001493152-26-035909.md) | [21.8](/filings/0001493152-26-035909.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,606) d](/filings/0001493152-24-043893.md) | [(2,022) d](/filings/0001493152-25-010146.md) | [2,408](/filings/0001641172-25-009180.md) | [(2,498) d](/filings/0001493152-25-011588.md) | [(2,833) d](/filings/0001493152-25-021007.md) | [1,702 d](/filings/0001493152-26-009411.md) | [(1,969)](/filings/0001493152-26-021637.md) | [(1,886) d](/filings/0001493152-26-035909.md) | [(2,986) d](/filings/0001493152-25-021007.md) | [(2,920) d](/filings/0001493152-26-009411.md) | [(2,257)](/filings/0001493152-26-021637.md) | [(3,028) d](/filings/0001493152-26-035909.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001493152-24-043893.md) | [9.2 d](/filings/0001493152-25-010146.md) | not reported | not reported | not reported | [10.0 d](/filings/0001493152-26-009411.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | [8.1](/filings/0001641172-25-009180.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [5,250](/filings/0001493152-23-039861.md) | [5,235](/filings/0001493152-24-018311.md) | [5,235](/filings/0001493152-24-030648.md) | [5,292](/filings/0001493152-24-043893.md) | [5,358](/filings/0001641172-25-009180.md) | [5,344](/filings/0001493152-25-011588.md) | [5,348](/filings/0001493152-25-021007.md) | [5,349](/filings/0001493152-26-021637.md) | [5,352](/filings/0001493152-26-035909.md) | [5,413](/filings/0001493152-25-021007.md) | [6,795](/filings/0001493152-26-021637.md) | [8,217](/filings/0001493152-26-035909.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,244,253 at 2026-08-03, from the cover of the [10-Q filed 2026-08-04](/filings/0001493152-26-035909.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.